<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01414803</url>
  </required_header>
  <id_info>
    <org_study_id>4-2008-0390</org_study_id>
    <nct_id>NCT01414803</nct_id>
  </id_info>
  <brief_title>Tolerability and Efficacy of Rosuvastatin - Fenofibrate Combine Therapy in Korean Patients With Combined Hyperlipidemia</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although the combination of statin and fenofibrate is one of the options for patients with
      combined hyperlipidemia, non-lipid effects of it has not been completely understood yet. In
      this study we compared the effects of rosuvastatin 10 mg/fenofibrate 160 mg combination and
      rosuvastatin 10 mg monotherapy on muscle and liver enzyme, homocysteine levels, kidney, blood
      glucose control, and blood cell counts.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of elevation of CK&gt;5x ULN or AST&gt;3x ULN or ALT&gt;3x ULN</measure>
    <time_frame>24 weeks after drug treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>rosuvastatin/fenofibrate combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>rosuvastatin 10 mg/fenofibrate 160 mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rosuvastatin monotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>rosuvastatin 10 mg per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipid modification</intervention_name>
    <description>rosuvastatin 10 mg/fenofibrate 160 mg per day</description>
    <arm_group_label>rosuvastatin/fenofibrate combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipid modification</intervention_name>
    <description>rosuvastatin 10 mg per day</description>
    <arm_group_label>rosuvastatin monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  mixed hyperlipidemia: total cholesterol levels higher than 220 mg/dL, triglyceride
             (TG) levels between 200 and 500 mg/dL, and low-density lipoprotein (LDL)-cholesterol
             levels higher than 130 mg/dL after 6-week diet/life style change

          -  Men and women who were between 20 and 70 years of age

          -  Having at least one history of: coronary artery disease, cerebrovascular disease or
             transient ischemic attack, peripheral vascular disease, or diabetes mellitus.

          -  Having risk factors at least two of: age ≥45 years in male or ≥55 years in female,
             elevated blood pressure (systolic blood pressure ≥130 mmHg or diastolic blood pressure
             ≥85 mmHg, or treatment of previously diagnosed hypertension), high-density lipoprotein
             (HDL)-cholesterol &lt;40 mg/dL, family history of coronary artery disease at age &lt;55
             years in male or &lt;65 years in female, central obesity (waist circumference ≥90 cm for
             male or ≥80 cm for female), fasting plasma glucose ≥110 mg/dL, or left ventricular
             hypertrophy on electrocardiogram

          -  Written informed consent.

        Exclusion Criteria:

          -  pregnant or breast-feeding

          -  uncontrolled hypertension

          -  uncontrolled diabetes mellitus

          -  thyroid dysfunction

          -  serum transaminase level &gt;2 times the upper limit of normal

          -  history of gall bladder disease

          -  chronic alcoholic

          -  serum creatinine level &gt;1.5 mg/dL

          -  history of myopathy

          -  history of acute myocardial infarction or acute stroke within 3 months before the
             study began

          -  acute or chronic infection or inflammation

          -  history of cancer

          -  history of adverse events associated with test drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Paterson JM, Smith SM, Simpson J, Grace OC, Sosunov AA, Bell JE, Antoni FA. Characterisation of human adenylyl cyclase IX reveals inhibition by Ca(2+)/Calcineurin and differential mRNA plyadenylation. J Neurochem. 2000 Oct;75(4):1358-67.</citation>
    <PMID>10987815</PMID>
  </reference>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2011</study_first_submitted>
  <study_first_submitted_qc>August 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2011</study_first_posted>
  <last_update_submitted>August 10, 2011</last_update_submitted>
  <last_update_submitted_qc>August 10, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2011</last_update_posted>
  <responsible_party>
    <name_title>Yangsoo Jang/Professor</name_title>
    <organization>Severance Hospital</organization>
  </responsible_party>
  <keyword>rosuvastatin, fenofibrate, creatine kinase, alanine aminotransferase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

